Conduit Pharmaceuticals(CDT) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CDT Conduit Pharmaceuticals

Watchlist

0.781
-0.109-12.25%

Close Mar 31 16:00 ET

0.800
+0.019+2.43%

Post 19:59 ET

4.84MMarket Cap-0.04P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Conduit Pharmaceuticals Awarded U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
BenzingaMar 31 08:31 ET
Express News | Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656
ReutersMar 31 08:35 ET
10-K: FY2024 Annual Report
SECMar 28 16:55 ET · Announcements
Conduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline Development
Quiver QuantitativeMar 19 08:42 ET
Express News | Conduit Pharmaceuticals - Results for Study With Charles River Laboratories Expected in Q2 2025
ReutersMar 19 08:36 ET
Express News | Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904
ReutersMar 19 08:30 ET

Comments

101877207

9 hours ago

$Conduit Pharmaceuticals (CDT.US)$ it just a dream😩😩

72055196

11 hours ago

$Conduit Pharmaceuticals (CDT.US)$ runner for today in after resistance break of 1.00

god will help us

11 hours ago

$Conduit Pharmaceuticals (CDT.US)$ when I mentioned at 1.01 it rise to 1.18 thanks market

Teddy123

11 hours ago

Pharmaceutical IP analysis

$Conduit Pharmaceuticals (CDT.US)$
The USPTO's grant of a composition of matter patent for Conduit's AZD1656 represents a significant milestone that substantially strengthens the company's competitive position. These patents are considered the gold standard in pharmaceutical IP protection, providing the strongest defense against generic competition by protecting the actual molecular structure rather than just its applications or formulations.
With this U.S. approval com...

Teddy123

11 hours ago

Biotech analysis

$Conduit Pharmaceuticals (CDT.US)$
This patent approval marks a pivotal inflection point for Conduit Pharmaceuticals' development strategy for AZD1656, their Glucokinase Activator targeting autoimmune conditions. The composition of matter patent—officially classified as a "drug substance" patent in the FDA's Orange Book—provides the critical IP foundation necessary before committing significant resources to the expensive clinical trial process.
The focus on Lupus and ANCA Vasculi...